Business Monitor International


France Pharmaceuticals & Healthcare Report

Published 06 March 2014

  • 121 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
France Pharmaceuticals & Healthcare Report

BMI View: A number of biologics will lose patent protection between now and 2015, which means that France's biosimilar substitution legislation will pave the way to cost savings in the healthcare system. However, we question the strength of this legislation, as development and manufacturing costs for these products are high and therefore actual cost savings secured through biosimilars may ultimately be limited. Furthermore, ongoing safety concerns may act as a barrier to the prescription of biosimilars

Headline Expenditure Projections

  • Pharmaceuticals: EUR33.75bn (US$44.55bn) in 2013 to EUR33.02bn (US$41.94bn) in 2014; -2.2% in local currency terms and -5.9% in US dollar terms.

  • Healthcare: EUR243.76bn (US$321.76bn) in 2013 to EUR250.01bn (US$317.51bn) in 2014; +2.6% in local currency terms and -1.3% in US dollar terms.

Risk/Reward Ratings: France is ranked fourth out of the 15 markets in BMI's Western Europe Pharmaceutical Risk/Reward Ratings (RRR) matrix for Q214, with a composite score of 70.9 out of the maximum 100 points. The country's Reward profile remains considerably less attractive than its risk score, reinforcing our view of the country's potential due to a stronger emphasis on the regulatory environment, which we regard as a major factor affecting the business environment for drugmakers, rather than on the basis of real opportunities for higher per-capita drug consumption.

Key Trends And Developments

As of January 1 2014, pharmacists in France have been legally permitted to substitute a biosimilar for an originator biological medicine. This follows the signing of the 2014 Social Security Financing Law in December 2013, which allows for the automatic registration of a biosimilar on the biosimilar register as soon as its marketing authorisation has been granted by the French National Agency for Medicines and Health Products Safety (ANSM).

In Q413, multinational drugmaker Sanofi recorded sales of EUR8.45bn (US$11.53bn), a 0.8% decrease on reported...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: France Pharmaceutical Sales, Historical Data and Forecasts
15
Healthcare Market Forecast
16
Table: France Healthcare Expenditure Trends, Historical Data And Forecasts
17
Table: France Government Healthcare Expenditure Trends, Historical Data And Forecasts
18
Table: France Private Healthcare Expenditure Trends, Historical Data And Forecasts
18
Prescription Drug Market Forecast
19
Table: France Prescription Drug Market Indicators, Historical Data and Forecasts
20
Patented Drug Market Forecast
20
Table: France Patented Drug Market Indicators, Historical Data And Forecasts
21
Generic Drug Market Forecast
22
Table: France Generic Drug Market Indicators, Historical Data And Forecasts
26
OTC Medicine Market Forecast
27
Table: France Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts
29
Pharmaceutical Trade Forecast
30
Table: France Pharmaceutical Trade Data And Forecasts (US$mn)
31
Table: France Pharmaceutical Trade Data And Forecasts (EURmn)
32
Other Healthcare Data
32
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
34
Economic Analysis
34
Real GDP By Expenditure
35
Risks To Outlook
39
Table: France - Economic Activity
40
Industry Risk Reward Ratings
41
Western Europe Risk/Reward Ratings
41
France Risk/Reward Ratings
46
Rewards
46
Risks
46
Market Overview
48
Industry Trends And Developments
49
Epidemiology
49
Prescription Drugs
50
Healthcare Financing
51
Public Hospitals
52
Table: Hospital Activity, 2005-2009
53
Table: Hospital Activity in Short-Stay Units, 2009
54
Table: Diagnostic & Therapeutic Procedures Performed in Public & Private Hospitals, 2009
55
Table: Regional Ranking Of Projected Physicians, 2017
57
Table: Projected Physicians, 2012-2017
57
Table: Medical Personnel, 2005-2010
58
Generic Drugs
58
Research & Development
59
Biotechnology
60
Clinical Trials
63
Regulatory Development
65
Intellectual Property Issues
67
Pricing & Reimbursement
68
Table: France Reimbursement Categories
68
Biosimilars
71
OTC Medicines
75
Competitive Landscape
77
Pharmaceutical Sector
77
Foreign Industry
79
Pharmaceutical Distribution
80
Pharmaceutical Retail Sector
81
Company Profile
83
Sanofi
83
Servier
92
Ipsen
96
Pfizer
100
GlaxoSmithKline
103
Novartis
106
Merck & Co
109
Demographic Forecast
111
Table: France's Population By Age Group, 1990-2020 ('000)
112
Table: France's Population By Age Group, 1990-2020 (% of total)
113
Table: France's Key Population Ratios, 1990-2020
114
Table: France's Rural And Urban Population, 1990-2020
114
Glossary
115
Methodology
117
Pharmaceutical Expenditure Forecast Model
117
Healthcare Expenditure Forecast Model
117
Notes On Methodology
118
Risk/Reward Ratings Methodology
119
Ratings Overview
120
Table: Pharmaceutical Risk/Reward Ratings Indicators
120
Indicator Weightings
121

The France Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's France Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the French pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for France to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
  • Target business opportunities and risks in the French pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in France.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc